Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

“Este contenido se encuentra unicamente en inglés”

Luis Gonzaga Paz-Ares
Luis Gonzaga Paz-Ares Jefe de Grupo
T +34 917 328 000 (Ext )
lpazares@ext.cnio.es

Investigadores

  • María Teresa Agullo
  • Irene Ferrer
  • Rocio García
  • Eva María Garrido
  • Santiago Ponce
  • María del Carmen Riesco

Investigador Clínico I

  • María Teresa Muñoz

Becarios Post-doctorales

  • Beatriz Soldevilla

Becarios Pre-Doctorales

  • Carlos Carretero
  • Santiago García
  • Ángela María Marrugal
  • Ángel Núñez
  • Laura Ojeda
  • Javier Ramos
  • Beatriz Rubio
  • Patricia Yagüe

Técnicos de Laboratorio

  • María Cristina Cirauqui
  • Patricia Cozar
  • Mirella Gallego
  • Laura García
  • Beatriz Gil
  • Rocío Suárez

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Our Unit is dedicated to the study of lung cancer, combining basic research studies with other more clinically oriented research studies, closer to solving the problems of lung cancer patients. The two main research areas of our Unit include: the identification of new molecular biomarkers that can be used in the clinic for diagnostic, prognostic and predictive purposes; and the development of novel treatment strategies that include targeted therapies and immunotherapeutics. For example, we have elucidated the molecular determinants of the oncogenicity of FGFRs, and have discovered biomarkers to monitor the efficacy of FGFR inhibitors in lung cancer. On the other hand, we have developed a patient-derived xenograft (PDX) platform of non-small-cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in bringing new drugs to the clinic (phase I trials), as well as in conducting practice-changing phase II/III trials in the fields of precision oncology and immuno-oncology.

Subir